Market Access Roadmap - Pharmaceutical Executive


Market Access Roadmap

Pharmaceutical Executive

Standardized planning

Over the past several years, market access has become an increasingly important topic. Given the tough economic situation, especially in a number of European markets, the national and local healthcare budgets in many countries have been cut significantly. Many countries have overhauled their pricing rules and introduced strict market access policies. With the introduction of cost-saving measures in various countries, market access has become a bottleneck to the successful launch of new products. Further compounding this situation is the loss of exclusivity of many key products and the drying of pharmaceutical pipelines, which has also caused a decrease in the budgets available for market research projects. This is especially the case for payer research, which is difficult and often costly to conduct due to the limited number of stakeholders able to participate.

The increased focus on market access results in an increased need for payer research and employees with in-depth market access experience to help execute this research. However, given that market access is a niche knowledge area; pharmaceutical companies are struggling to find experienced professionals. The lack of employees with in-depth market access knowledge has also contributed to inconsistencies in the market access research conducted throughout the company. Additionally, the economy and the changing healthcare environment have forced many large pharmaceutical companies to cut team sizes—leaving the same amount of work, if not more, to be done by fewer employees.

As a result, many companies are looking for streamlined methods to share market access best practices. In order to effectively share best practices across their entire product portfolio and reduce overall costs, companies have begun developing a unified roadmap for payer market research. The goal of this process is to work more efficiently given the limited resources available to prevent the unnecessary duplication of research, look for potential research synergies, and ensure the execution of only the most critical research efforts throughout an asset's lifecycle.

Roadmap for success

Developing a unified roadmap allows for knowledge sharing by highlighting the value of market research planning and defining the necessary payer research initiatives and activities throughout the lifecycle of an asset (figure). A standardized roadmap necessitates internal alignment across therapeutic areas, brands, and global markets. It can also be used as a training tool for employees who are unfamiliar with market access planning; it allows employees to quickly understand the market access environment and the relevant stakeholders in different countries across various therapeutic areas. With this tool, employees are challenged to take a high-level perspective on a company's product portfolio, to identify assets with similar indications, and/or development milestones and to assess the key research needs within the asset's lifecycle.

Market Acces Research Roadmap Across the Product Lifecycle
The roadmap provides a standardized structure and centralized storage place for market access information. Since the roadmap outlines items like key project objectives and appropriate research sample, it allows companies to efficiently generate requests for proposals for market research studies, ensuring that only the most critical research is executed at each product phase. Additionally, the roadmap can function as a tool for budget planning and ensuring all the important payer research milestones for each product are reached.


blog comments powered by Disqus

Source: Pharmaceutical Executive,
Click here